Belite Bio, Inc (BLTE) Prices 6M ADS IPO at $6/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq set to open higher as CPI, bank earnings take focus; IBM tumbles
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Belite Bio Announces Pricing of $36 Million Initial Public Offering
April 28, 2022 6:59 PM EDTSAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (Belite or the Company), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and metabolic diseases, today announced the pricing of its initial public offering of 6 million American Depositary Shares (ADSs) at a public offering price per ADS of $6.00. Each ADS represents one ordinary share of Belite. In addition, Belite has granted the underwriters a 30-day option to purchase an additional 900,000 ADSs at the initial public offering price, less the underwriting... More
